Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLACIER: Safety and Tolerability of Glatiramer Acetate 40 mg/mL TIW vs 20 mg/mL Daily
NCT01874145Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2013
- Primary completion
- Apr 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jun 2013; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01874145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874145.